Document is current
Any future updates will be listed below
-
Authors
Moreno-Treviño, María Guadalupe https://orcid.org/0000-0002-4746-3630
González-Salazar, Francisco https://orcid.org/0000-0003-2832-4771
León-Cachón, Rafael Baltazar Reyes https://orcid.org/0000-0002-1639-6869
Rivera-Silva, Gerardo https://orcid.org/0000-0003-2587-5914
Hernández-Coria, Mayra Ivonne https://orcid.org/0009-0003-3303-4522
Acedo-Zúñiga, Javier https://orcid.org/0000-0002-0002-1800
de la Peña-Mireles, Ivan Alejandro https://orcid.org/0009-0003-4654-1582
Elizondo-Murillo, José Luis https://orcid.org/0009-0007-5364-4888
Garibay-Orijel, Claudio https://orcid.org/0000-0001-9261-0030
- License Information
-
More Information
Article History
Received: 31 August 2025
Accepted: 27 January 2026
First Online: 4 February 2026
Declarations
:
: The research protocol and informed consent were reviewed and approved by the Subcommittee of Research Ethics of the Health Department of the State of Tamaulipas, Mexico, an ethics committee registered with the National Bioethics Commission (CONBIOÉTICA) under code RF 011/2019/SCEI. Final authorization was granted under official approval number 003926, validating both the methodological design and all documents associated with the study. Written informed consent was obtained from all participants before enrollment in the study. The consent form clearly stated the study objectives, the procedures to be performed (including blood culture collection and subsequent genomic sequencing), potential risks and benefits, and measures to ensure confidentiality. Participation was entirely voluntary, and participants were informed of their right to withdraw at any time without any impact on their medical care. Signed copies of the informed consent documents are archived in accordance with institutional and national regulations. The study was conducted in full compliance with the ethical principles outlined in the Declaration of Helsinki (2024 revision), ensuring respect for human subjects, the protection of their health and rights, and adherence to internationally recognized standards for biomedical research.
: Not applicable.
: IAP-M, JLE-M, JA-Z, and CG-O are named inventors on the patent related to the Agata Sepsis ® Platform (WO2023128747A1). All other authors declare that they have no competing interests.
